Journal of Clinical Oncology, Vol 17, Issue 9
(September), 1999: 2762
© 1999 American Society for Clinical Oncology
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
W.K. Alfred Yung,
Michael D. Prados,
Ricardo Yaya-Tur,
Steven S. Rosenfeld,
Michael Brada,
Henry S. Friedman,
Robert Albright,
Jeffrey Olson,
Susan M. Chang,
Alison M. O'Neill,
Allan H. Friedman,
Janet Bruner,
Nancy Yue,
Margaret Dugan,
Sara Zaknoen,
Victor A. Levin,
for the Temodal Brain Tumor Group
From the University of Texas M.D. Anderson Cancer Center, Houston, TX; University of California, San Francisco, San Francisco, CA; University of Alabama, Birmingham, AL; Duke University, Durham, NC; University of Cincinnati, Cincinnati, OH; Emory Clinic, Atlanta, GA; Johns Hopkins University, Baltimore, MD; Schering-Plough Pharmaceuticals, Kenilworth, NJ; Hôpital de la Pitié-Salpetrière, Paris, France; and Royal Marsden Hospital, Surrey, United Kingdom.
Address reprint requests to W.K. Alfred Yung, MD, University of Texas M.D. Anderson Cancer Center, Department of Neuro-oncology, Box 100, 1515 Holcombe Blvd, Houston, TX 77030; emailyung@ manderson.org.
PURPOSE: To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse.
PATIENTS AND METHODS: This open-label, multicenter, phase II trial enrolled 162 patients (intent-to-treat [ITT] population). After central histologic review, 111 patients were confirmed to have had an anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma. Chemotherapy-naive patients were treated with temozolomide 200 mg/m2/d. Patients previously treated with chemotherapy received temozolomide 150 mg/m2/d; the dose could be increased to 200 mg/m2/d in the absence of grade 3/4 toxicity. Therapy was administered orally on the first 5 days of a 28-day cycle.
RESULTS: Progression-free survival (PFS) at 6 months, the primary protocol end point, was 46% (95% confidence interval, 38% to 54%). The median PFS was 5.4 months, and PFS at 12 months was 24%. The median overall survival was 13.6 months, and the 6- and 12-month survival rates were 75% and 56%, respectively. The objective response rate determined by independent central review of gadolinium-enhanced magnetic resonance imaging scans of the ITT population was 35% (8% complete response [CR], 27% partial response [PR]), with an additional 26% of patients with stable disease (SD). The median PFS for patients with SD was 4.4 months, with 33% progression-free at 6 months. Maintenance of progression-free status and objectively assessed response (CR/PR/SD) were both associated with health-related quality-of-life (HQL) benefits. Adverse events were mild to moderate, with hematologic side effects occurring in less than 10% of patients.
CONCLUSION: Temozolomide demonstrated good single-agent activity, an acceptable safety profile, and documented HQL benefits in patients with recurrent AA.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Oncologist,
June 1, 2009;
14(6):
621 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. OSHIRO, H. TSUGU, F. KOMATSU, T. OHMURA, M. OHTA, S. SAKAMOTO, T. FUKUSHIMA, and T. INOUE
Efficacy of Temozolomide Treatment in Patients with High-grade Glioma
Anticancer Res,
March 1, 2009;
29(3):
911 - 917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-x. Cheng, X. Zhang, and B.-L. Liu
Health-related quality of life in patients with high-grade glioma
Neuro-oncol,
January 1, 2009;
11(1):
41 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wick, M. Platten, and M. Weller
New (alternative) temozolomide regimens for the treatment of glioma
Neuro-oncol,
January 1, 2009;
11(1):
69 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hoffmann, I. Fichtner, M. Lemm, P. Lienau, H. Hess-Stumpp, A. Rotgeri, B. Hofmann, and U. Klar
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
Neuro-oncol,
January 1, 2009;
11(2):
158 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Y. Wen, A. D. Norden, and J. Drappatz
Antiangiogenic Therapies for Malignant Gliomas
ASCO Educational Book,
January 1, 2009;
2009(1):
113 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zheng, D. Bocangel, R. Ramesh, S. Ekmekcioglu, N. Poindexter, E. A. Grimm, and S. Chada
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3842 - 3851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Desjardins, D. A. Reardon, J. E. Herndon II, J. Marcello, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, L. Bailey, et al.
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clin. Cancer Res.,
November 1, 2008;
14(21):
7068 - 7073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Maxwell, S. P. Johnson, R. E. McLendon, D. W. Lister, K. S. Horne, A. Rasheed, J. A. Quinn, F. Ali-Osman, A. H. Friedman, P. L. Modrich, et al.
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
Clin. Cancer Res.,
August 1, 2008;
14(15):
4859 - 4868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med.,
July 31, 2008;
359(5):
492 - 507.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nagane, K. Kobayashi, A. Ohnishi, S. Shimizu, and Y. Shiokawa
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
Jpn. J. Clin. Oncol.,
December 21, 2007;
(2007)
hym132v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Loghin, M. D. Prados, P. Wen, L. Junck, F. Lieberman, H. Fine, K. L. Fink, M. Metha, J. Kuhn, K. Lamborn, et al.
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Clin. Cancer Res.,
December 1, 2007;
13(23):
7133 - 7138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
Clin. Cancer Res.,
November 15, 2007;
13(22):
6712 - 6718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm
Central Nervous System Tumors
Mayo Clin. Proc.,
October 1, 2007;
82(10):
1271 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
J. Clin. Oncol.,
September 10, 2007;
25(26):
4127 - 4136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kunwar, M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, J. H. Sampson, Z. Ram, P. H. Gutin, R. D. Gibbons, et al.
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
J. Clin. Oncol.,
March 1, 2007;
25(7):
837 - 844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Rubie, J. Chisholm, A. S. Defachelles, B. Morland, C. Munzer, D. Valteau-Couanet, V. Mosseri, C. Bergeron, C. Weston, C. Coze, et al.
Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group New Agents Group Study
J. Clin. Oncol.,
November 20, 2006;
24(33):
5259 - 5264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
J. Clin. Oncol.,
November 20, 2006;
24(33):
5271 - 5276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Maxwell, S. P. Johnson, J. A. Quinn, R. E. McLendon, F. Ali-Osman, A. H. Friedman, J. E. Herndon II, K. Bierau, J. Bigley, D. D. Bigner, et al.
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
Mol. Cancer Ther.,
October 1, 2006;
5(10):
2531 - 2539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. H Mabasa and S. C. Taylor
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia
Journal of Oncology Pharmacy Practice,
June 1, 2006;
12(2):
105 - 111.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Reardon, J. A. Quinn, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al.
Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results
J. Nucl. Med.,
June 1, 2006;
47(6):
912 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. F. Lang and M. R. Gilbert
Diffusely Infiltrative Low-Grade Gliomas in Adults
J. Clin. Oncol.,
March 10, 2006;
24(8):
1236 - 1245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol.,
March 10, 2006;
24(8):
1253 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist,
February 1, 2006;
11(2):
165 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Warren, A. A. Aikin, M. Libucha, B. C. Widemann, E. Fox, R. J. Packer, and F. M. Balis
Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors
J. Clin. Oncol.,
October 20, 2005;
23(30):
7646 - 7653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Quinn, A. Desjardins, J. Weingart, H. Brem, M. E. Dolan, S. M. Delaney, J. Vredenburgh, J. Rich, A. H. Friedman, D. A. Reardon, et al.
Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
J. Clin. Oncol.,
October 1, 2005;
23(28):
7178 - 7187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cohen, J. R. Johnson, and R. Pazdur
Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Clin. Cancer Res.,
October 1, 2005;
11(19):
6767 - 6771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Langer and M. P. Mehta
Current Management of Brain Metastases, With a Focus on Systemic Options
J. Clin. Oncol.,
September 1, 2005;
23(25):
6207 - 6219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Cheng, S. P. Johnson, S. T. Keir, J. A. Quinn, F. Ali-Osman, C. Szabo, H. Li, A. L. Salzman, M. E. Dolan, P. Modrich, et al.
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft
Mol. Cancer Ther.,
September 1, 2005;
4(9):
1364 - 1368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Momota, E. Nerio, and E. C. Holland
Perifosine Inhibits Multiple Signaling Pathways in Glial Progenitors and Cooperates With Temozolomide to Arrest Cell Proliferation in Gliomas In vivo
Cancer Res.,
August 15, 2005;
65(16):
7429 - 7435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-B. Wasserfallen, S. Ostermann, S. Leyvraz, and R. Stupp
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
Neuro-oncol,
April 1, 2005;
7(2):
189 - 195.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A R Giovagnoli, A Silvani, E Colombo, and A Boiardi
Facets and determinants of quality of life in patients with recurrent high grade glioma
J. Neurol. Neurosurg. Psychiatry,
April 1, 2005;
76(4):
562 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Athanassiou, M. Synodinou, E. Maragoudakis, M. Paraskevaidis, C. Verigos, D. Misailidou, D. Antonadou, G. Saris, K. Beroukas, and P. Karageorgis
Randomized Phase II Study of Temozolomide and Radiotherapy Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme
J. Clin. Oncol.,
April 1, 2005;
23(10):
2372 - 2377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Neff, B. C. Beard, L. J. Peterson, P. Anandakumar, J. Thompson, and H.-P. Kiem
Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy
Blood,
February 1, 2005;
105(3):
997 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Greanya, S. Taylor, F H. BscPharm, J Barnett, and B Thiessen
Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis
Journal of Oncology Pharmacy Practice,
December 1, 2004;
10(4):
201 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. F. Paz, R. Yaya-Tur, I. Rojas-Marcos, G. Reynes, M. Pollan, L. Aguirre-Cruz, J. L. Garcia-Lopez, J. Piquer, M.-J. Safont, C. Balana, et al.
CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas
Clin. Cancer Res.,
August 1, 2004;
10(15):
4933 - 4938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Raizer, M. G. Malkin, M. Kleber, and L. E. Abrey
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
Neuro-oncol,
July 1, 2004;
6(3):
247 - 252.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. K. Pueschel
Integrative Tumor Board: Glioblastoma Multiforme: Neurooncology
Integr Cancer Ther,
June 1, 2004;
3(2):
151 - 152.
[PDF]
|
|
|
|
|
|
|
S. S. Agarwala, J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, M. Atkins, A. Buzaid, D. Skarlos, and E. M. Rankin
Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study
J. Clin. Oncol.,
June 1, 2004;
22(11):
2101 - 2107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ostermann, C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune, L. A. Decosterd, and R. Stupp
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
Clin. Cancer Res.,
June 1, 2004;
10(11):
3728 - 3736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Broniscer and A. Gajjar
Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist
Oncologist,
April 1, 2004;
9(2):
197 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Hammond, J. R. Eckardt, J. G. Kuhn, S. L. Gerson, T. Johnson, L. Smith, R. L. Drengler, E. Campbell, G. R. Weiss, D. D. Von Hoff, et al.
A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
Clin. Cancer Res.,
March 1, 2004;
10(5):
1645 - 1656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Wagner, K. R. Crews, L. C. Iacono, P. J. Houghton, C. E. Fuller, M. B. McCarville, R. E. Goldsby, K. Albritton, C. F. Stewart, and V. M. Santana
Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
Clin. Cancer Res.,
February 1, 2004;
10(3):
840 - 848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Wong and A. Berkenblit
The Role of Topotecan in the Treatment of Brain Metastases
Oncologist,
February 1, 2004;
9(1):
68 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Prados, W.K. A. Yung, H. A. Fine, H. S. Greenberg, L. Junck, S. M. Chang, M. K. Nicholas, H. I. Robins, M. P. Mehta, K. L. Fink, et al.
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
Neuro-oncol,
January 1, 2004;
6(1):
33 - 37.
[PDF]
|
|
|
|
|
|
|
S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Neuro-oncol,
January 1, 2004;
6(1):
38 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Vera, L. Djafari, S. Faivre, J.-S. Guillamo, K. Djazouli, M. Osorio, F. Parker, C. Cioloca, B. Abdulkarim, J.-P. Armand, et al.
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors
Ann. Onc.,
January 1, 2004;
15(1):
161 - 171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al.
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Ann. Onc.,
December 1, 2003;
14(12):
1715 - 1721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. van den Bent, W. Grisold, D. Frappaz, R. Stupp, J. P. Desir, T. Lesimple, C. Dittrich, M. J. A. de Jonge, A. Brandes, M. Frenay, et al.
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme
Ann. Onc.,
December 1, 2003;
14(12):
1732 - 1734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang, et al.
Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma
Clin. Cancer Res.,
November 1, 2003;
9(14):
5370 - 5379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Neuro-Oncology Working Group of the German Can
Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma
J. Clin. Oncol.,
September 1, 2003;
21(17):
3276 - 3284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Pollack, J. M. Boyett, A. J. Yates, P. C. Burger, F. H. Gilles, R. L. Davis, J. L. Finlay, and for the Children's Cancer Group
The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience
Neuro-oncol,
July 1, 2003;
5(3):
197 - 207.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M.J. van den Bent, M.J.B. Taphoorn, A.A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J.M. Kros, C.C.D. van der Rijt, Ch.J. Vecht, et al.
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
J. Clin. Oncol.,
July 1, 2003;
21(13):
2525 - 2528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Fine, P. Y. Wen, E. A. Maher, E. Viscosi, T. Batchelor, N. Lakhani, W. D. Figg, B. W. Purow, and C. B. Borkowf
Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
J. Clin. Oncol.,
June 15, 2003;
21(12):
2299 - 2304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Jaeckle, K. R. Hess, W.K. A. Yung, H. Greenberg, H. Fine, D. Schiff, I. F. Pollack, J. Kuhn, K. Fink, M. Mehta, et al.
Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study
J. Clin. Oncol.,
June 15, 2003;
21(12):
2305 - 2311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Bodell, N. W. Gaikwad, D. Miller, and M. S. Berger
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide: Implications for the Treatment of Low-Grade Adult and Pediatric Brain Tumors
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2003;
12(6):
545 - 551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
Neuro-oncol,
April 1, 2003;
5(2):
128 - 138.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. van den Bent, O. Chinot, W. Boogerd, J. Bravo Marques, M. J. B. Taphoorn, J. M. Kros, C. C. D. van der Rijt, C. J. Vecht, N. De Beule, and B. Baron
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
Ann. Onc.,
April 1, 2003;
14(4):
599 - 602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frenay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. M. Rodier, et al.
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma
Ann. Onc.,
April 1, 2003;
14(4):
603 - 614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al.
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
J. Clin. Oncol.,
February 15, 2003;
21(4):
646 - 651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Buckner, D. Gesme Jr, J. R. O'Fallon, J. E. Hammack, S. Stafford, P. D. Brown, R. Hawkins, B. W. Scheithauer, B. J. Erickson, R. Levitt, et al.
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
J. Clin. Oncol.,
January 15, 2003;
21(2):
251 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. S. Lashford, P. Thiesse, A. Jouvet, T. Jaspan, D. Couanet, P. D. Griffiths, F. Doz, J. Ironside, K. Robson, R. Hobson, et al.
Temozolomide in Malignant Gliomas of Childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study
J. Clin. Oncol.,
December 15, 2002;
20(24):
4684 - 4691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Gilbert, H. S. Friedman, J. F. Kuttesch, M. D. Prados, J. J. Olson, G. H. Reaman, and S. L. Zaknoen
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
Neuro-oncol,
October 1, 2002;
4(4):
261 - 267.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Antonadou, M. Paraskevaidis, G. Sarris, N. Coliarakis, I. Economou, P. Karageorgis, and N. Throuvalas
Phase II Randomized Trial of Temozolomide and Concurrent Radiotherapy in Patients With Brain Metastases
J. Clin. Oncol.,
September 1, 2002;
20(17):
3644 - 3650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seiter, D. Liu, T. Loughran, A. Siddiqui, P. Baskind, and T. Ahmed
Phase I Study of Temozolomide in Relapsed/Refractory Acute Leukemia
J. Clin. Oncol.,
August 1, 2002;
20(15):
3249 - 3253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Bocangel, S. Finkelstein, S. C. Schold, K. K. Bhakat, S. Mitra, and D. M. Kokkinakis
Multifaceted Resistance of Gliomas to Temozolomide
Clin. Cancer Res.,
August 1, 2002;
8(8):
2725 - 2734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-J. Hwu, S. E. Krown, K. S. Panageas, J. H. Menell, P. B. Chapman, P. O. Livingston, L. J. Williams, C. J. Quinn, and A. N. Houghton
Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial
J. Clin. Oncol.,
June 1, 2002;
20(11):
2610 - 2615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, G. Zupi, E. Bonmassar, and G. Graziani
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
Blood,
March 15, 2002;
99(6):
2241 - 2244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stupp, P.-Y. Dietrich, S. O. Kraljevic, A. Pica, I. Maillard, P. Maeder, R. Meuli, R. Janzer, G. Pizzolato, R. Miralbell, et al.
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
J. Clin. Oncol.,
March 1, 2002;
20(5):
1375 - 1382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wick, A. Wick, J. B. Schulz, J. Dichgans, H. P. Rodemann, and M. Weller
Prevention of Irradiation-induced Glioma Cell Invasion by Temozolomide Involves Caspase 3 Activity and Cleavage of Focal Adhesion Kinase
Cancer Res.,
March 1, 2002;
62(6):
1915 - 1919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Miller, C. R. Williams, D. J. Buchsbaum, and G. Y. Gillespie
Intratumoral 5-Fluorouracil Produced by Cytosine Deaminase/5-Fluorocytosine Gene Therapy Is Effective for Experimental Human Glioblastomas
Cancer Res.,
February 1, 2002;
62(3):
773 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bafaloukos, H. Gogas, V. Georgoulias, E. Briassoulis, G. Fountzilas, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, and P. Kosmidis
Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group
J. Clin. Oncol.,
January 15, 2002;
20(2):
420 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Khan, J. J. Raizer, M. G. Malkin, K. A. Bazylewicz, and L. E. Abrey
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Neuro-oncol,
January 1, 2002;
4(1):
39 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Gururangan, I. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon II, J. M. Provenzale, R. E. McLendon, S. Tourt-Uhlig, et al.
Phase I study of GliadelTM wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
Neuro-oncol,
October 1, 2001;
3(4):
246 - 250.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M.J. van den Bent, F. Keime-Guibert, A.A. Brandes, M.J.B. Taphoorn, J.M. Kros, F.A.L.M. Eskens, and A.F. Carpentier
Temozolomide chemotherapy in recurrent oligodendroglioma
Neurology,
July 24, 2001;
57(2):
340 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O.-L. Chinot, S. Honore, H. Dufour, M. Barrie, D. Figarella-Branger, X. Muracciole, D. Braguer, P.-M. Martin, and F. Grisoli
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
J. Clin. Oncol.,
May 1, 2001;
19(9):
2449 - 2455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Kokkinakis, R. M. Hoffman, E. P. Frenkel, J. B. Wick, Q. Han, M. Xu, Y. Tan, and S. C. Schold
Synergy between Methionine Stress and Chemotherapy in the Treatment of Brain Tumor Xenografts in Athymic Mice
Cancer Res.,
May 1, 2001;
61(10):
4017 - 4023.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Ino, R. A. Betensky, M. C. Zlatescu, H. Sasaki, D. R. Macdonald, A. O. Stemmer-Rachamimov, D. A. Ramsay, J. G. Cairncross, and D. N. Louis
Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis
Clin. Cancer Res.,
April 1, 2001;
7(4):
839 - 845.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al.
Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
Neuro-oncol,
January 1, 2001;
3(1):
46 - 54.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Osoba, M. Brada, M. D. Prados, and W.K. A. Yung
Effect of disease burden on health-related quality of life in patients with malignant gliomas
Neuro-oncol,
October 1, 2000;
2(4):
221 - 228.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. J. Patel, G. B. Elion, P. J. Houghton, S. Keir, A. E. Pegg, S. P. Johnson, M. E. Dolan, D. D. Bigner, and H. S. Friedman
Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft
Clin. Cancer Res.,
October 1, 2000;
6(10):
4154 - 4157.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. S. Friedman, T. Kerby, and H. Calvert
Temozolomide and Treatment of Malignant Glioma
Clin. Cancer Res.,
July 1, 2000;
6(7):
2585 - 2597.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. G. Cairncross
Understanding low-grade glioma: A decade of progress
Neurology,
April 11, 2000;
54(7):
1402 - 1403.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Agarwala and J. M. Kirkwood
Temozolomide, a Novel Alkylating Agent with Activity in the Central Nervous System, May Improve the Treatment of Advanced Metastatic Melanoma
Oncologist,
April 1, 2000;
5(2):
144 - 151.
[Abstract]
[Full Text]
|
|
|
|
